211 related articles for article (PubMed ID: 19558341)
1. Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases.
Murota H; Katayama I
Expert Opin Pharmacother; 2009 Aug; 10(11):1859-67. PubMed ID: 19558341
[TBL] [Abstract][Full Text] [Related]
2. Emedastine difumarate inhibits histamine-induced collagen synthesis in dermal fibroblasts.
Murota H; Bae S; Hamasaki Y; Maruyama R; Katayama I
J Investig Allergol Clin Immunol; 2008; 18(4):245-52. PubMed ID: 18714531
[TBL] [Abstract][Full Text] [Related]
3. Clinical study of the therapeutic efficacy and safety of emedastine difumarate versus terfenadine in the treatment of seasonal allergic rhinitis.
Corrado ME; Radicioni MM; Hartwig J; Assandri A; Oldeman HG; Mion A
Arzneimittelforschung; 2004; 54(10):660-5. PubMed ID: 15553105
[TBL] [Abstract][Full Text] [Related]
4. Emedastine difumarate versus loratadine in chronic idiopathic urticaria: a randomized, double-blind, controlled European multicentre clinical trial.
Pons-Guiraud A; Nekam K; Lahovsky J; Costa A; Piacentini A
Eur J Dermatol; 2006; 16(6):649-54. PubMed ID: 17229605
[TBL] [Abstract][Full Text] [Related]
5. Emedastine and allergic conjunctivitis: new preparation. Poor assessment.
Prescrire Int; 2001 Apr; 10(52):39-40. PubMed ID: 11718155
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human eosinophil chemotaxis in vitro by the anti-allergic agent emedastine difumarate.
el-Shazly AE; Masuyama K; Samejima Y; Eura M; Ishikawa T
Immunopharmacol Immunotoxicol; 1996 Nov; 18(4):587-95. PubMed ID: 8933171
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model.
D'Arienzo PA; Leonardi A; Bensch G
Clin Ther; 2002 Mar; 24(3):409-16. PubMed ID: 11952024
[TBL] [Abstract][Full Text] [Related]
8. [Effects of emedastine eyedrops on acute seasonal allergic conjunctivitis in children].
Endre L
Orv Hetil; 2003 Apr; 144(14):665-7. PubMed ID: 12795028
[TBL] [Abstract][Full Text] [Related]
9. Effect of tecastemizole on pulmonary and cutaneous allergic inflammatory responses.
Lever R; Hefni A; Moffatt JD; Paul W; Page CP
Clin Exp Allergy; 2007 Jun; 37(6):909-17. PubMed ID: 17517105
[TBL] [Abstract][Full Text] [Related]
10. Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders.
Smith SM; Gums JG
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):813-22. PubMed ID: 19545214
[TBL] [Abstract][Full Text] [Related]
11. [The prompt effect of emedastine eye drop and the safety of its permanent use in children suffering from acute seasonal allergic conjunctivitis].
Endre L
Orv Hetil; 2007 Feb; 148(6):251-4. PubMed ID: 17344175
[TBL] [Abstract][Full Text] [Related]
12. Adhesive explant culture of allergic nasal mucosa: effect of emedastine difumarate, an anti-allergic drug.
Okubo K; Pawankar R; Gotoh M; Yagi T
Jpn J Pharmacol; 1999 Mar; 79(3):351-7. PubMed ID: 10230864
[TBL] [Abstract][Full Text] [Related]
13. [Antihistamines in the treatment of allergic rhinitis--update 2008/2009].
Kruszewski J
Otolaryngol Pol; 2009 Sep; 63(7):5-10. PubMed ID: 20564892
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle-controlled study.
Liu RF; Wu XX; Wang X; Gao J; Zhou J; Zhao Q
Int Forum Allergy Rhinol; 2017 Apr; 7(4):393-398. PubMed ID: 27869354
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
[TBL] [Abstract][Full Text] [Related]
16. Involvement of blockade of leukotriene B(4) action in anti-pruritic effects of emedastine in mice.
Andoh T; Kuraishi Y
Eur J Pharmacol; 2000 Oct; 406(1):149-52. PubMed ID: 11011046
[TBL] [Abstract][Full Text] [Related]
17. Emerging drugs for ocular allergy.
Leonardi A
Expert Opin Emerg Drugs; 2005 Aug; 10(3):505-20. PubMed ID: 16083326
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological profile and clinical efficacy of transdermal patch containing emedastine difumarate (ALLESAGA
Tanida N; Akiyama K; Terahara T
Nihon Yakurigaku Zasshi; 2018; 152(5):246-255. PubMed ID: 30393257
[TBL] [Abstract][Full Text] [Related]
19. Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use.
Yanni JM; Stephens DJ; Parnell DW; Spellman JM
J Ocul Pharmacol; 1994; 10(4):665-75. PubMed ID: 7714410
[TBL] [Abstract][Full Text] [Related]
20. Suplatast tosilate inhibits eosinophil production and recruitment into the skin in murine contact sensitivity.
Satoh T; Sasaki G; Wu MH; Yokozeki H; Katayama I; Nishioka K
Clin Immunol; 2003 Sep; 108(3):257-62. PubMed ID: 14499249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
